CAM
IONS icon

CG Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

CG Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,800
Closed -$729K – 128
2014
Q4 		$729K Buy
+11,800
New +$582K 0.29% 77

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CG Asset Management's IONS Position: Q1 2015 in Review

CG Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2015, closing a stake of 11,800 shares — an estimated $729K sold.

CG Asset Management first reported a position in IONS in Q4 2014 and held it in 1 quarter. The position peaked at $729K in Q4 2014. 339 funds tracked by Wall St. Rank hold IONS as of Q1 2015.

  • CG Asset Management reported no remaining Ionis Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • CG Asset Management sold 11,800 Ionis Pharmaceuticals shares in Q1 2015, an estimated $729K.
  • CG Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • CG Asset Management's Ionis Pharmaceuticals position peaked at $729K in Q4 2014.
  • 339 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2015.

Based on CG Asset Management's 13F filing for Q1 2015, filed 24 Apr 2015.